PROTECT

A coordinated stroke treatment program to prevent recurrent thromboembolic events

B. Ovbiagele, J. L. Saver, A. Fredieu, S. Suzuki, N. McNair, A. Dandekar, T. Razinia, Stella Kidwell

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment (PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge. Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year. Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease (baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100% for antithrombotic agents, 68 to 97% for statins, 42 to 90% for angiotensin- converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70% for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100% of the intervention cohort. Conclusion: Implementation of this single-center, systems-based, inhospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.

Original languageEnglish (US)
Pages (from-to)1217-1222
Number of pages6
JournalNeurology
Volume63
Issue number7
StatePublished - Oct 12 2004
Externally publishedYes

Fingerprint

Stroke
Recurrence
Secondary Prevention
Life Style
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fibrinolytic Agents
Angiotensin Receptor Antagonists
Therapeutics
Brain Ischemia
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Atherosclerosis
Demography

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ovbiagele, B., Saver, J. L., Fredieu, A., Suzuki, S., McNair, N., Dandekar, A., ... Kidwell, S. (2004). PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology, 63(7), 1217-1222.

PROTECT : A coordinated stroke treatment program to prevent recurrent thromboembolic events. / Ovbiagele, B.; Saver, J. L.; Fredieu, A.; Suzuki, S.; McNair, N.; Dandekar, A.; Razinia, T.; Kidwell, Stella.

In: Neurology, Vol. 63, No. 7, 12.10.2004, p. 1217-1222.

Research output: Contribution to journalArticle

Ovbiagele, B, Saver, JL, Fredieu, A, Suzuki, S, McNair, N, Dandekar, A, Razinia, T & Kidwell, S 2004, 'PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events', Neurology, vol. 63, no. 7, pp. 1217-1222.
Ovbiagele B, Saver JL, Fredieu A, Suzuki S, McNair N, Dandekar A et al. PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology. 2004 Oct 12;63(7):1217-1222.
Ovbiagele, B. ; Saver, J. L. ; Fredieu, A. ; Suzuki, S. ; McNair, N. ; Dandekar, A. ; Razinia, T. ; Kidwell, Stella. / PROTECT : A coordinated stroke treatment program to prevent recurrent thromboembolic events. In: Neurology. 2004 ; Vol. 63, No. 7. pp. 1217-1222.
@article{1b3654e7d0494256907dbdc5d371697a,
title = "PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events",
abstract = "Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment (PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge. Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year. Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease (baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100{\%} for antithrombotic agents, 68 to 97{\%} for statins, 42 to 90{\%} for angiotensin- converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70{\%} for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100{\%} of the intervention cohort. Conclusion: Implementation of this single-center, systems-based, inhospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.",
author = "B. Ovbiagele and Saver, {J. L.} and A. Fredieu and S. Suzuki and N. McNair and A. Dandekar and T. Razinia and Stella Kidwell",
year = "2004",
month = "10",
day = "12",
language = "English (US)",
volume = "63",
pages = "1217--1222",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - PROTECT

T2 - A coordinated stroke treatment program to prevent recurrent thromboembolic events

AU - Ovbiagele, B.

AU - Saver, J. L.

AU - Fredieu, A.

AU - Suzuki, S.

AU - McNair, N.

AU - Dandekar, A.

AU - Razinia, T.

AU - Kidwell, Stella

PY - 2004/10/12

Y1 - 2004/10/12

N2 - Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment (PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge. Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year. Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease (baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100% for antithrombotic agents, 68 to 97% for statins, 42 to 90% for angiotensin- converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70% for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100% of the intervention cohort. Conclusion: Implementation of this single-center, systems-based, inhospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.

AB - Objective: To assess the impact of the Preventing Recurrence of Thromboembolic Events through Coordinated Treatment (PROTECT) Program on achievement of its eight secondary prevention goals at the time of discharge. Methods: Achievement rates for the eight program goals at time of discharge were compared in all patients discharged from a university hospital-based stroke service with a diagnosis of ischemic stroke or TIA during a 1-year period after implementation of the PROTECT Program vs rates obtained from a comparable group of patients admitted to the same service during the preceding year. Results: Demographic and medical features were comparable in the baseline and intervention cohorts for all patients with cerebral ischemia presumed due to large-vessel atherosclerosis or small-vessel disease (baseline year n = 117, intervention n = 130). Implementation rates in patients without specific contraindications increased for all four medication goals: 97 to 100% for antithrombotic agents, 68 to 97% for statins, 42 to 90% for angiotensin- converting enzyme inhibitors/angiotensin receptor blockers, and 14 to 70% for diuretics. Although data were not collected on baseline lifestyle instruction rates, instruction in the program's four lifestyle interventions was achieved by discharge in 100% of the intervention cohort. Conclusion: Implementation of this single-center, systems-based, inhospital program to initiate secondary stroke prevention therapies was associated with a substantial increase in treatment utilization at the time of hospital discharge.

UR - http://www.scopus.com/inward/record.url?scp=5344256249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344256249&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1217

EP - 1222

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -